Continuing To Add To Allergan In A Portfolio Beating The Market

| About: Allergan plc (AGN)


Eaton Vance, Priceline, and McGraw-Hill continue to fuel this portfolio.

Allergan is an anchor on the portfolio but I continue to believe and add to my position.

I'm up 6.06% on this portfolio since its inception versus a 1.85% gain in the S&P 500 for the same duration.

During 2015 I decided that I wanted a portfolio which mimicked the S&P 500 without owning an index fund to do it. From the inception of the portfolio I have always at most maintained twelve stocks and this portfolio is up 6.06% so far compared to the 1.85% gain in the S&P 500. The portfolio is up right now because of the significant outperformance of Eaton Vance (NYSE:EV), Priceline Group (NASDAQ:PCLN), and McGraw-Hill (MHFI). The intention of this portfolio is for long-term investments (minimum of three months), not trades.

I evaluate the portfolio quarterly after earnings season and I only make change-outs if the fundamentals have changed in a company. I try to hold two stocks in each of the following categories: value, dividend growth, growth, and growth & income; and four speculative names. I also try to have at least one stock in each sector. The portfolio is currently yielding 0.84% but I'm not worried about yield for this portfolio.

Just the other day I decided to add to my position in Allergan (NYSE:AGN). I'd like to give a quick synopsis of the stock right now and provide an update for the entire portfolio. Please keep in mind that I do individual homework on these stocks through articles here on SA and you can look up the tickers with their corresponding articles, but you should always do your own homework too.


Allergan is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products. The stock appears to be inexpensively valued on next year's earnings estimates while having great earnings growth expectations for the near-term. The company pays no dividend but has decent financial efficiency ratios. I believe the stock offers great value as long as it remains below the $276 level.

Now it's time for an update on the entire portfolio from inception.



incl. DIV


Eaton Vance Corp



The Priceline Group Inc.



McGraw-Hill Companies Inc.



Gilead Sciences Inc.




O'Reilly Automotive, Inc.




Skyworks Solutions Inc.




Alphabet Inc.




Biogen Inc.




Allergan plc



RHI JUN 17 2016 45.00 PUT




GILD MAY 20 2016 95.00 PUT






My portfolio is moderately risky. Financial planners typically recommend this type of portfolio for investors who have three- to 10-year investment horizons and who are concerned by volatility but not preoccupied by it. Such portfolios often generate a healthy stream of current income. So far this portfolio is beating the overall market but the key is to keep tabs on all your stocks regularly as well.

Roughly 79% of my holdings are centered in North America because I feel the rest of the world is struggling right now. I have a growth portfolio for all intents and purposes. I have a lot of exposure to the healthcare industry and aggressive growth stocks. I don't have any exposure to the consumer defensive sector, hard assets, slow growth, or speculative growth stocks. My portfolio's stock exposure is biased toward aggressively priced growth stocks. I have a good mix of small, medium, and large companies. I want to further diversify my portfolio by increasing my exposure to value stocks however. I anticipate this portfolio to produce high long-term returns but with quite a bit of volatility along the way.

Disclaimer: This article is in no way a recommendation to buy or sell any stock mentioned. This article is meant to serve as a journal for myself as to the rationale of why I bought/sold this stock when I look back on it in the future. These are only my personal opinions and you should do your own homework. Only you are responsible for what you trade and happy investing!

Disclosure: I am/we are long AGN, BIIB, EV, GILD, GOOG, MHFI, ORLY, PCLN, SWKS.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

About this article:

Author payment: $35 + $0.01/page view. Authors of PRO articles receive a minimum guaranteed payment of $150-500. Become a contributor »
Problem with this article? Please tell us. Disagree with this article? .